Interestingly, these results were not always consistent
There is anecdotal evidence that pancreatic transplantation may be effective in managing diabetic gastroparesis [85]
GLP-1 receptor agonists, such as semaglutide, marketed as Ozempic (subcutaneous, once weekly) and Rybelsus (oral, once daily) for type 2 diabetes mellitus, and as Wegovy (subcutaneous, once weekly) for obesity irrespective of diabetes status, have become a cornerstone therapy owing to their efficacy in improving glycemic control and promoting weight loss [5]
As a precaution, patients with severe kidney disease may be advised to use alternative B12 forms
Creative learning from other fields: adjacent brands are reframing health solutions (food, fitness, wellness) around GLP-1 habits and mindsets, using pharmas omnichannel playbook to drive demand